The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.
